Aortic valve sclerosis

Article written and reviewed by Dr Luca Moretti

Aortic valve sclerosis is focal thickening, increased echogenicity or calcification of the aortic cusps without hemodynamically significant obstruction. The valve appears abnormal, but systolic opening remains sufficient and, according to the EACVI/ASE classification, peak transvalvular velocity is no higher than 2.5 m/s. It is therefore different from aortic stenosis, although in many patients the two belong to the same calcific disease spectrum.

The finding is common in older adults and is often incidental, but by itself it does not create enough pressure overload to explain dyspnea, angina or syncope. When these symptoms are present, underestimated stenosis should first be excluded and other causes sought, including coronary artery disease, heart failure, arrhythmias, anemia or pulmonary disease; attributing every symptom to a simple "calcified valve" easily leads to diagnostic error.

Sclerosis has two distinct but related clinical meanings. On the one hand, it may represent the early stage of calcific disease that will progress to stenosis in a proportion of patients; on the other, it is associated with greater cardiovascular risk because it shares age and predisposing factors with atherosclerosis and kidney disease. This association, however, does not demonstrate that a nonobstructive valve directly causes myocardial infarction or stroke.

Pathogenesis of early calcific disease

The old concept of passive wear has been replaced by a model of biologically active disease. The aortic side of the cusps is exposed to oscillatory flow and mechanical stress, especially near the base. Endothelial dysfunction increases permeability and allows apoB-containing lipoproteins to enter the matrix.

Accumulation of lipoproteins and oxidized phospholipids activates an inflammatory response in which macrophages, mast cells and lymphocytes release cytokines and proteases, promoting matrix remodeling and microinjury. In this process, lipoprotein(a), which carries oxidized phospholipids, is particularly relevant because of strong genetic and observational associations with calcification and stenosis.

Valvular interstitial cells can shift from a quiescent phenotype to myofibroblast-like and osteoblast-like states. BMP, Wnt/β-catenin and Runx2 signaling, oxidative stress and phosphate metabolism promote mineralized nodules. Microcalcification increases stiffness and further concentrates mechanical stress, fueling propagation.

Fibrosis and calcium are not synonymous. In early stages, fibrous thickening may predominate, whereas macroscopic calcium appears and increases with age. Bicuspid valves accumulate asymmetric stress and become stenotic earlier; in kidney disease, hyperphosphatemia and mineral abnormalities accelerate the process.

Associated factors include age, male sex, hypertension, smoking, LDL cholesterol, diabetes, obesity and kidney disease. Overlap with atherosclerosis is evident during the initiation phase, but advanced valve disease is dominated by fibrosis and mineralization. This distinction helps explain the different response to drug therapy.

Variants at the LPA locus and elevated Lp(a) levels support a causal contribution. This does not yet mean that anti-Lp(a) therapy is indicated for sclerosis: trials must demonstrate an effect on progression and outcomes. Measurement may be appropriate for global cardiovascular risk assessment according to lipid guidelines.

Mitral annular, aortic and coronary calcification often coexist. They may represent a systemic vulnerability to mineralization but have different anatomical consequences. Aortic sclerosis is not simply a "plaque" located on a valve and should not be treated with coronary procedures.

The initiation and propagation phases do not necessarily share the same therapeutic targets. LDL lowering can prevent atherosclerosis and perhaps limit some early exposures, but once calcific nodules and osteogenic pathways are established, progression may become less lipid-dependent; for this reason, trials conducted mainly in established stenosis do not definitively answer the question of very early prevention, but they also do not justify unproven specific therapies.

Calcification is therefore a biologically active process in which inflammation, matrix remodeling and osteogenic differentiation reinforce one another until the cusp becomes progressively stiffer. This transition explains why initially nonobstructive sclerosis can evolve, in some patients, into true hemodynamically significant stenosis.

The renin-angiotensin system, inflammation and bone metabolism have been proposed as targets. Retrospective associations with ACE inhibitors, osteoporosis or bone-active drugs do not establish efficacy. Practice should remain anchored to trials and independent indications because interfering with bone metabolism in an older patient can cause harm without valve benefit.

Epidemiology and prognostic significance

In population studies, prevalence rises sharply after age 65 and may affect about one quarter of older adults, with estimates varying according to definition, echocardiographic quality and cohort selection. It is less common in younger people, in whom a thickened cusp should prompt consideration of bicuspid morphology, rheumatic sequelae or another disorder.

In the Cardiovascular Health Study, sclerosis without stenosis was associated with higher cardiovascular mortality and a greater risk of myocardial infarction. The association persisted after adjustment for known factors, but an observational study does not prove that valve calcification is the mechanism. It may be an integrated marker of cumulative exposure, inflammation and predisposition.

The finding therefore prompts a comprehensive cardiovascular assessment: blood pressure, lipids, diabetes, smoking, kidney function, physical activity, weight and the presence of atherosclerotic disease. It does not automatically justify coronary angiography or antiplatelet therapy. Each preventive intervention follows absolute risk and its own indications.

Progression to stenosis is real but not inevitable. Longitudinal studies report transition in a minority over several years, with average rates on the order of a few percentage points per year and wide variability. An average percentage does not predict the individual: some remain stable for decades, while others accelerate.

More extensive calcium, higher baseline velocity, a bicuspid aortic valve, age, kidney disease, diabetes and elevated Lp(a) are associated with progression. The increase tends to be nonlinear and may accelerate as calcium increasingly impairs leaflet motion.

Isolated sclerosis does not cause valve-related ventricular hypertrophy. If echocardiography shows thickened walls, more likely causes include hypertension, aging, cardiomyopathy or amyloidosis. Confusing association with causation can lead to overestimation of valve disease.

A mild systolic murmur may arise from turbulence across irregular cusps, but anemia, pregnancy, hyperthyroidism and high-output states can generate a murmur through a nonobstructive valve. Doppler identifies the source. A new increase in murmur intensity warrants reassessment, particularly when symptoms are present.

The probability of progression should be communicated as a range rather than a destiny. A cohort average includes both stable patients and rapid progressors; uncertainty decreases after two comparable examinations. Unchanged velocity for years and mild calcium allow more widely spaced follow-up, whereas a reproducible increase changes the trajectory.

The presence of sclerosis on CT performed for coronary assessment is not automatically equivalent to the echocardiographic diagnosis. CT depicts calcium but does not measure obstruction; a high calcium burden may justify echocardiography, whereas minimal calcium in an asymptomatic older adult can be contextualized. The report should distinguish anatomical calcification from valve function.

In epidemiological studies, the associated risk may also reflect unmeasured coronary calcification and inflammation. Sclerosis adds information but is not included as a coronary disease equivalent in the major risk scores. The choice of statin or antihypertensive therapy derives from overall risk rather than from an arbitrary multiplier.

Echocardiographic diagnosis and differential diagnosis

Transthoracic echocardiography is the reference test. Long-axis and short-axis views show focal thickening, increased reflectivity and calcified areas while preserving sufficient systolic cusp separation. Color Doppler excludes significant regurgitation; continuous-wave Doppler measures velocity from multiple windows.

Practical criteria defining sclerosis include:

• Thickening or calcification of one or more aortic cusps.
• Sufficient residual mobility to avoid a hemodynamically relevant reduction in opening.
• Peak transaortic velocity no higher than 2.5 m/s.
• Absence of a significant gradient attributable to valvular stenosis.
• Absence of a specific ventricular response due to obstructive valve pressure overload.

A velocity of 2.6-2.9 m/s already falls within mild stenosis in the EACVI/ASE classification, not sclerosis. The boundary should be interpreted at normal blood pressure and after excluding high flow. Velocity should not be estimated with pulsed-wave instead of continuous-wave Doppler or from a single misaligned window.

Valve area is not required in clear-cut sclerosis and may produce spurious values if the left ventricular outflow tract diameter is inaccurate. If velocity, gradient and morphology are discordant, measurements and flow conditions should be reviewed. Stenosis should not be diagnosed from the visual impression of calcium alone.

Bicuspid morphology may be obscured by calcification. Systolic short-axis views, commissural position and the raphe should be sought; TEE or CT may clarify anatomy if the information changes follow-up or planning. In a young person, focal "sclerosis" requires particular attention to congenital morphology.

Rheumatic heart disease causes commissural fusion and retraction, often with regurgitation and mitral involvement. Degenerative calcific sclerosis more typically affects the base of the cusps while initially leaving the free edges mobile. A stenotic bicuspid or rheumatic valve should not be reclassified as sclerosis solely because velocity is low in the presence of low flow.

Calcification of the annulus or aortic root may project onto the valve. Reverberation and acoustic shadowing can simulate masses. CT quantifies calcium but is not routinely indicated in simple sclerosis; it becomes useful when discordant stenosis, aortopathy or coronary disease is suspected for other reasons.

Papillary fibroelastoma, Lambl excrescences, vegetations and thrombi are mobile masses with morphology different from calcification. Fever, embolism or new regurgitation requires TEE and an endocarditis pathway, not a label of sclerosis. Calcification may coexist with infection.

Magnetic resonance imaging is not needed for routine diagnosis and visualizes calcium poorly, but it can assess myocardium and flow when symptoms remain unexplained. Noncontrast CT measures valvular calcium and is validated in discordant stenosis, not as a screening test for every sclerotic finding.

An apparently elevated velocity may result from sampling in the left ventricular outflow tract, contamination by mitral regurgitation or Doppler interrogation of the wrong jet. Conversely, misalignment underestimates obstruction. Review of spectral envelopes and acoustic windows is necessary when a number does not match the image.

The mean gradient increases with the square of velocity and is flow-sensitive. In true sclerosis it remains low, but a patient with anemia or an arteriovenous fistula may have modestly elevated values without a stenotic valve area. Correcting the high-output state and repeating the study can prevent a persistent misclassification.

Nodular calcification near a subaortic membrane or dynamic obstruction can produce elevated nonvalvular velocities. The contour of the Doppler signal, pulsed-wave sampling along the outflow tract and imaging localize the acceleration. The term sclerosis describes the cusps, not every ejection murmur in an older adult.

Treatment and follow-up

There is no valve treatment indicated for sclerosis without obstruction. Surgery, TAVI and valvuloplasty provide no benefit and introduce risks. The patient should understand that "calcified" does not mean "needs replacement", but also does not mean the finding should be ignored indefinitely.

The SALTIRE, SEAS and ASTRONOMER trials did not show that statins or lipid-lowering combinations slow progression of calcific aortic stenosis. Statins are prescribed for LDL cholesterol and atherosclerotic prevention according to cardiovascular risk, not to dissolve valve calcium. Stopping them because they do not treat the valve would be equally incorrect.

Cardiovascular risk-factor control includes smoking cessation, blood pressure, diabetes, lipids, weight, physical activity and kidney function. These measures reduce cardiovascular events even though they have not been shown to stop the valvular process. Preventive benefit should not be described as specific treatment for sclerosis.

No anticalcific drug, bisphosphonate, denosumab, vitamin or supplement is approved to halt the disease. Mineral metabolism should be corrected in kidney disease according to nephrology indications. Calcium or vitamin D supplementation should not be changed without an independent clinical reason.

Follow-up frequency is individualized. Mild sclerosis with Vmax well below 2.5 m/s, no symptoms and low risk may be reassessed clinically and by echocardiography after several years; marked calcium, velocity close to the threshold, bicuspid morphology or kidney disease justify shorter intervals. Guidelines do not mandate annual echocardiography for everyone.

The development of exertional dyspnea, angina, syncope, reduced functional capacity or a change in the murmur prompts earlier reassessment. Because isolated sclerosis is asymptomatic, these events are a signal to investigate progression or another disease. Waiting until the next scheduled interval may be inappropriate.

A useful report documents morphology, visual calcium burden, Vmax, gradient when measurable, regurgitation and ventricular function. Writing only "aortic sclerosis" without velocity makes it impossible to distinguish stability from transition to stenosis at subsequent follow-up.

Antibiotic prophylaxis is not required for native sclerosis. Oral hygiene and infection control are recommended for general health. Antiplatelet therapy is not indicated by the valve finding and follows atherosclerotic disease or other independent indications only.

A heart-healthy diet reduces atherosclerotic risk, blood pressure and diabetes, but no food decalcifies the cusps. Commercial products claiming chelation or "valve cleansing" lack evidence and may interact with anticoagulants or kidney function. Education prevents dangerous substitution for prescribed therapy.

Physical activity is not limited by isolated sclerosis. Exercise prescription follows functional capacity, coronary disease, blood pressure and other conditions. If exertion causes symptoms, the response should not be permanent exercise avoidance without diagnosis, but assessment for progressive stenosis, ischemia or arrhythmia.

Before noncardiac surgery, documented sclerosis without symptoms and without change does not require the pathway used for severe stenosis. A new murmur or an old unquantified examination may justify echocardiography if the result would change management. The diagnosis and date should be available during preoperative assessment.

Progression, complications and clinical communication

The principal specific evolution is progression to stenosis. The first hemodynamic sign is a persistent increase in velocity beyond the upper limit for sclerosis; gradient then rises and valve area falls. Acceleration may be slow and only approximately linear, so prediction should be updated with actual measurements.

When mild stenosis develops, the patient enters a different pathway with its own severity classification and follow-up intervals. It is incorrect to retain the label of sclerosis for reassurance or to diagnose severe stenosis from visual calcification alone. Hemodynamic function determines the transition.

Coronary and cerebrovascular events are more frequent in cohorts with sclerosis, but management is that of cardiovascular prevention. Blood pressure, LDL cholesterol, diabetes and smoking are treatable targets. Sclerosis may provide an opportunity to identify neglected risk without itself becoming an improper indication for drug therapy.

In advanced kidney disease, progression may be rapid and is associated with diffuse calcification. Follow-up should be coordinated with nephrology, taking transplant candidacy and volume status into account. Low velocity in a low-flow patient does not exclude important anatomical stenosis.

In younger patients, the diagnosis should be reconsidered because an isolated degenerative process is less expected. Bicuspid valve, familial hypercholesterolemia, kidney disease, radiation therapy and metabolic disorders enter the differential diagnosis. CT is not automatic, but history should be expanded.

Communication should avoid two extremes: calling the finding harmless and ending follow-up, or presenting it as stenosis inevitably destined for TAVI. The accurate formulation is that the valve is abnormal but nonobstructive, the risk of progression is variable and cardiovascular risk factors require independent management.

Individual prognosis depends more on age, comorbidity and atherosclerosis than on the absent gradient. Patients who progress to stenosis assume the prognosis of the new severity; those who remain stable do not develop heart failure from sclerosis alone. A plan based on Doppler, risk and symptoms allows change to be recognized without overmedicalizing a common finding.

When velocity increases, the report should provide an annualized change only if the interval and study quality are adequate. A change of a few hundredths of a meter per second falls within measurement variability. Credible progression means a concordant trend in morphology, Doppler and, in later stages, ventricular response.

Sclerosis may coexist with cardiac amyloidosis, which in older adults causes thick walls and heart failure. A nonobstructive valve does not explain this picture; voltages, strain, extracardiac history and dedicated imaging guide the diagnosis. This distinction prevents a treatable cardiomyopathy from being attributed to calcium.

A proportionate follow-up system is preferable both to abandonment and to automatic annual echocardiography. Recording Vmax, morphology, progression factors and the indication for the next examination makes the plan verifiable and enables the next clinician to recognize when sclerosis has become stenosis.